Abstract: The present invention relates to an effect pigment comprising a plate-shaped non-metallic substrate and at least one copper-containing coating, wherein the average particle size D50 of the effect pigment is more than 5 ?m and the copper content of the effect pigment is in a range from 3 to 70 wt.-%, relative to the total weight of the effect pigment. The invention furthermore relates to a method for producing the latter and use of the effect pigment in anti-fouling coatings.

Abstract: A system (10) for removing a pipettable substance from a pre-filled container (20), which is closed off by a lid (30) having at least one opening area (40), comprises an opening tool (100) having a tube (110), which has a cross-section corresponding substantially to the shape of the opening area and which comprises at a distal end (120) an endpiece (140) extending substantially obliquely relative to the longitudinal axis of the tube, which moves a part of the lid (30) located inside the opening area (40) towards the container when the opening tool is applied, so as to form an opening in the lid, and a point of attack (150) for a transporting tool (200). The opening tool (100) is designed to remain on the container (20) after use.

Abstract: The present invention relates to platelet-shaped zinc-magnesium pigments, wherein the platelet-shaped zinc-magnesium pigments comprise the 40.8 to 67.8 mol % of zinc, 32.2 to 59.2 mol % of magnesium and 0 to 7 mol % of Mn, Li, Be, Y, Sn, Al, Ti, Fe, Cu and mixtures thereof, based in each case on the total molar amount of the elements Zn, Mg, Mn, Be, Y, Li, Sn, Al, Ti, Fe and Cu, where the molar percentages add up to 100 mol %, and the median thickness h50 of the pigments is less than 1 ?m. The invention further relates to the use and production of these pigments.

Abstract: The present invention relates to a method to improve the activity of engineered U7 snRNAs used in the context of RNA-based therapeutics; particularly in exon skipping, exon inclusion, and mRNA eradication strategies. The resulting modified U7 snRNAs are useful for treating neuromuscular diseases, in particular Duchenne neuromuscular dystrophy, myotonic dystrophy DM1 and spinal muscular atrophy.

Abstract: The present invention relates to improved compositions and methods for delivering and expressing therapeutic genes in mammals. More particularly, the invention stems from the unexpected discovery that a remarkable, massive and widespread therapeutic gene delivery and expression is obtained in mammals when a therapeutic gene is incorporated in a viral vector and administered both into the CSF and into the blood of the mammal. Such a combined administration leads to a surprising and substantial therapeutic benefit in the mammal as compared to administration in one single site, and further enables the use of reduced doses of the virus. The invention may be used in any mammal, including human subjects, and is particularly suited to treat multi-systemic diseases, such as motor neuron or lysosomal disorders, where widespread expression of a therapeutic gene is desirable.

Abstract: The present invention relates to an effect pigment comprising a plate-shaped non-metallic substrate and at least one copper-containing coating, wherein the average particle size D50 of the effect pigment is more than 5 ?m and the copper content of the effect pigment is in a range from 3 to 70 wt.-%, relative to the total weight of the effect pigment. The invention furthermore relates to a method for producing the latter and use of the effect pigment in anti-fouling coatings.

Abstract: The invention relates to a device for evaluating the distal motor skills of the upper limbs of a person, which includes a main bearing surface (1) for all or part of an upper limb, a measurement means including two push members (2, 3), each of which is provided with a bearing surface (20, 30) lying in a plane parallel to and different from that of said main surface (1), and each of which is coupled to a force sensor capable of generating a signal relating to the force exerted by the individual on said bearing surface, and a control system coupled to the measurement means, said control system making it possible to count a number of alternating pushes on each bearing surface. According to the invention, the push members (or keys) (2, 3) are screwed onto the force sensor, and each force sensor has a precision of around 0.01%.

Abstract: A gripper unit for handling a vessel for receiving biological material is proposed, inter alia. The vessel has a lid which can assume an open position and a closed position. The gripper unit comprises a gripper for gripping and releasing the vessel, and a lid holder, for holding a lid in a defined position in relation to the vessel. The defined position is an open position of the lid.

Abstract: A system (10) for removing a pipettable substance from a pre-filled container (20), which is closed off by a top (30) having at least one opening area (40), comprises an opening tool (100) having a tube (110), which has a cross-section corresponding substantially to the shape of the opening area and which comprises at a distal end (120) an endpiece (140) extending substantially obliquely relative to the longitudinal axis of the tube, which moves a part of the top (30) located inside the opening area (40) towards the container when the opening tool is applied, so as to form an opening in the top, and a point of attack (150) for a transporting tool (200). The opening tool (100) is designed to remain on the container (20) after use.

Abstract: A gripper unit for handling a vessel for receiving biological material is proposed, inter alia. The vessel has a lid which can assume an open position and a closed position. The gripper unit comprises a gripper for gripping and releasing the vessel, and a lid holder, for holding a lid in a defined position in relation to the vessel. The defined position is an open position of the lid.

Abstract: The present invention relates to improved methods for processing fluids and to a fluid processing device (1) for use in a centrifuge comprising: (a) a first holder (14) form-fit to the shape of a first tube (18) for holding said first tube (18) whereby said first tube (18) has a first cross section (A1); and (b) a second holder (22) form-fit to the shape of a second tube (26) for holding said second tube (26) whereby said second tube (26) has a second cross section (A2) that is different from said first cross section (A1). With the fluid processing devices and the methods according to the invention, it is possible to simplify the centrifugal processing steps for a given fluid processing sequence and to automate them.

Abstract: The invention relates to the diagnosis, the follow-up and the evaluation of the efficacy of a treatment of a muscular dystrophy by detection of microRNA in a body fluid, in particular in the urine.

Abstract: The present invention relates to a nucleic acid molecule containing a sequence of tricyclo nucleosides joined by internucleoside phosphorothioate linkage. The invention also relates to synthetic antisense oligonucleotides and to methods employing the same.

Abstract: The present invention relates to improved methods for processing fluids and to a fluid processing device (1) for use in a centrifuge comprising: (a) a first holder (14) form-fit to the shape of a first tube (18) for holding said first tube (18) whereby said first tube (18) has a first cross section (A1); and (b) a second holder (22) form-fit to the shape of a second tube (26) for holding said second tube (26) whereby said second tube (26) has a second cross section (A2) that is different from said first cross section (A1). With the fluid processing devices and the methods according to the invention, it is possible to simplify the centrifugal processing steps for a given fluid processing sequence and to automate them.

Abstract: An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.

Abstract: The invention relates to a sample container, comprising a housing which forms a sample space for receiving a sample and has at least one circular opening which extends in a channel-shaped manner into the sample space, and further comprising a spherical closing element, wherein the diameter of the closing element only exceeds the diameter of the opening channel in at least one (closing) portion to such an extent that the closing element can be fixed in a force-locked manner by its largest circumference in the closing portion, wherein the spherical closing element is in contact with the housing, and the opening channel between the closing portion and the inner opening forms a protrusion which reduces the opening cross section of the opening channel with respect to the opening cross section in the closing portion.

Abstract: Fluid processing tube for use in optical analysis comprising at least one first portion being made from a first material suitable for optical analysis and being configured to include two optical paths of different lengths, and at least one second portion connected to said first portion and being made from a second material different from said first material.

Abstract: Methods for increasing the efficiency of target tissue penetration of an adeno-associated virus (AAV) vector in a patient are provided. In some aspects, the methods involve inhibiting the interaction of the serum protein galectin 3 binding protein (G3BP) with AAV vector. Further provided are methods for reducing tissue distribution of a virus or for neutralizing a virus harbored by an organ destined for transplant, or newly transplanted, by administering a composition comprising G3BP.

Abstract: A system (10) for removing a pipettable substance from a pre-filled container (20), which is closed off by a top (30) having at least one opening area (40), comprises an opening tool (100) having a tube (110), which has a cross-section corresponding substantially to the shape of the opening area and which comprises at a distal end (120) an endpiece (140) extending substantially obliquely relative to the longitudinal axis of the tube, which moves a part of the top (30) located inside the opening area (40) towards the container when the opening tool is applied, so as to form an opening in the top, and a point of attack (150) for a transporting tool (200). The opening tool (100) is designed to remain on the container (20) after use.

Abstract: The present invention relates to a method to improve the activity of engineered U7 snRNAs used in the context of RNA-based therapeutics; particularly in exon skipping, exon inclusion, and mRNA eradication strategies. The resulting modified snRNAs are useful for treating neuromuscular diseases, in particular Duchenne neuromuscular dystrophy, myotonic dystrophy DM1 and spinal muscular atrophy.